Dr. Cobbs is only partly in the loop. His comments about a 20% long tail if listened to carefully is in the form of a hypothetical. Dr. Linda Liau suggested a 20%-25% long tail 2.5 years ago for DCVax-L which was before German patients had a chance to have their results included in that long tail and before Linda Powers made her comments about unanticipated survival at the most recent ASM. He is not trying to downplay DCVax-L in this presentation but he obviously was trying to make the most out of his opportunity to talk about his own trial which is having some initial good results as well as far as 2 year survival is concerned. I say obviously since he mentioned his trial results last as compared to everything prior so that what was said last would be remembered as a strong conclusion. This is a common technique and was employed just like a conclusion in an abstract might be written. Good for him and good for GBM patients. I am on the side of good science and patients first wherever that leads. Best wishes.
News 
Market Data 
Discover 
AI
